Rx Prescripttion Only-YMYL Medical Content

Imacent 400 mg

Name: Imacent 400 mg (Generic Imatinib in Bangladesh)
Brand: Generic
SKU: IMACENT-400
Price: 90.00 BDT
Availability: InStock
Rating: 4.8 (15 reviews)

Imatinib Mesylate 400mg tablets – Incepta Pharmaceuticals Ltd.

Approved for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic, accelerated, and blast phases; Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL); gastrointestinal stromal tumors (GIST) — unresectable/metastatic and adjuvant after resection; and several rarer conditions including myelodysplastic/myeloproliferative diseases and aggressive systemic mastocytosis.

83.3%

Estimated 10-year overall survival in chronic-phase CML (IRIS trial, 10.9-year follow-up)

<1 in 3

CML patients survived 5 years before imatinib — now most have near-normal life expectancy

82.8%

Cumulative complete cytogenetic response rate at 10 years in CML (IRIS trial)

20+ yrs

In clinical use — the drug that defined the era of targeted cancer therapy

Confirm diagnosis and Philadelphia chromosome / BCR-ABL status

For CML and Ph+ ALL — requires confirmed Philadelphia chromosome (t(9;22) translocation) or BCR-ABL1 fusion gene by cytogenetics, FISH, or PCR. For GIST — requires confirmed KIT (CD117) expression or PDGFRA/KIT mutation testing.

Identify CML phase or GIST setting

CML phase (chronic, accelerated, or blast) determines the starting dose (400mg or 600mg). For GIST, 400mg is used for both unresectable/metastatic disease and adjuvant therapy after resection for at-risk patients.

Assess baseline blood counts, liver, and kidney function

Complete blood count, liver enzymes, and kidney function required before starting. Imatinib can cause cytopenias (low blood counts), liver enzyme elevation, and fluid retention — baselines determine monitoring thresholds.

Review current medications — especially warfarin and CYP3A4 interactions

Imatinib is a CYP3A4 substrate and CYP2D6 inhibitor — many drug interactions exist. Warfarin interaction is particularly important; patients on warfarin should switch to low-molecular-weight heparin or be monitored very closely.

Important safety information: Imatinib can cause severe fluid retention including pleural effusion, pericardial effusion, pulmonary edema, and ascites — particularly in older patients and those at higher doses. Severe cytopenias (very low blood counts) are common especially in accelerated phase/blast crisis. Hepatotoxicity including severe liver enzyme elevation has occurred. Avoid grapefruit juice, which increases imatinib exposure. Embryo-fetal toxicity — not for use in pregnancy.

Medical Oncologist Review

Board-certified oncologist · 12+ years in thoracic malignancies

“Imatinib changed everything — it turned CML from a disease where fewer than one in three patients survived five years into one where most patients on therapy can expect a near-normal lifespan. Over twenty years of data, it remains one of the most effective cancer treatments ever developed. For newly diagnosed chronic-phase CML, the question today is whether imatinib or a second-generation TKI is the right first choice — a conversation worth having with your hematologist based on your specific risk score and long-term goals.”

Content reviewed against FDA prescribing information, NCCN Guidelines v2.2024, and published Phase III trial data. Last updated June 2026.

Ready to discuss Tagrisso with your care team?

These steps help you have an informed conversation. A confirmed EGFR mutation result is the starting point for any treatment decision.

Questions to ask my healthcare provider

What questions should I ask my hematologist about starting imatinib for CML?

Here are key questions to bring to your hematologist — imatinib has over two decades of clinical data, which means the conversations around monitoring milestones, treatment-free remission goals, and sequencing with second-generation TKIs are more mature and evidence-based than almost any other drug we’ve covered.

Before confirming imatinib as your treatment

Has my Philadelphia chromosome or BCR-ABL1 fusion been confirmed, and what is my specific CML phase — chronic, accelerated, or blast crisis?
What is my Sokal or ELTS risk score, and does it put me in a low, intermediate, or high risk category?
Why is imatinib being recommended rather than a second-generation TKI like dasatinib or nilotinib — particularly given that second-generation drugs achieve deeper and faster molecular responses in some patients?
Are there clinical trials I should know about at this point?

About the treatment milestones — understanding what success looks like

What are the specific response milestones I should be hitting, and at what timepoints — complete hematologic response, complete cytogenetic response, major molecular response?
What happens if I don’t hit a milestone on schedule — does that mean switching to a different TKI, or adjusting my dose?
How will BCR-ABL levels be measured and reported, and what does the International Scale percentage mean practically?
At what point would a bone marrow biopsy be repeated versus monitoring by peripheral blood PCR only?

About dosing and administration

My dose is 400mg once daily — should I take it at the same time each day, and does timing matter?
The drug should be taken with food and a large glass of water — how much food, and does the type of food matter?
What happens if I miss a dose — take it the same day when I remember, or skip until the next scheduled dose?
Should I avoid grapefruit and grapefruit juice throughout treatment?

About fluid retention — the most distinctive monitoring requirement

What does fluid retention from imatinib look like in practice — periorbital swelling around the eyes in the morning, ankle swelling, weight gain?
How quickly can fluid retention develop, and at what point does it require dose reduction or a diuretic?
Do I have any pre-existing heart or kidney condition that makes fluid retention more dangerous?
Will I be weighed at each visit, and what rate of weight gain should prompt me to call?

About blood count monitoring

How often will my blood counts be checked, especially in the first few months?
What levels of neutropenia, anemia, or thrombocytopenia would require dose interruption?
What symptoms of low blood counts — fever, unusual bleeding or bruising, profound fatigue — should prompt an urgent call?

About liver monitoring

How often will liver function tests be checked?
What symptoms of liver problems should I watch for, and at what point would they lead to stopping treatment?

About muscle cramps — a commonly underestimated side effect

How common are muscle cramps with imatinib, and what can help prevent or treat them?
Is there a role for calcium, magnesium, or quinine supplements — and are those safe alongside imatinib?
Do cramps tend to improve over time, or persist throughout treatment?

About managing nausea

Since nausea is very common early on, are there anti-nausea strategies to have ready from day one?
Does taking it with a larger or specific type of meal help more than others?
Does the nausea typically improve after the first few weeks?

About the warfarin and medication interaction

Am I currently on warfarin or any other anticoagulant — and if so, what is the management plan?
Are there other medications in my current list that interact significantly with imatinib through CYP3A4 — including supplements, herbal products, or St. John’s Wort?
If I need a new medication from any other doctor while on imatinib, what should they know?

About my specific situation

Do I have any pre-existing liver or heart conditions that affect my dose or monitoring plan?
If I am of childbearing potential, what contraception is required during treatment, and is there any possibility of treatment-free remission before family planning?
Does my kidney function affect anything about how imatinib is dosed or monitored?

About the long-term picture — treatment-free remission

If I achieve a deep molecular response (MR4 or MR4.5) and sustain it, am I a candidate for a treatment-free remission trial — attempting to stop imatinib under close monitoring?
What criteria need to be met before a treatment-free remission attempt, and how long would I need to be in deep response first?
What happens if BCR-ABL levels rise after stopping — is restarting imatinib expected to work again?
Is there any benefit to switching to a second-generation TKI now specifically to optimize my chances of achieving treatment-free remission later?

About the longer road

If imatinib eventually stops working due to resistance, what would the next step be — BCR-ABL mutation testing and then a specific TKI based on which mutation is found?
Are there patient assistance or generic access programs if the branded product cost is a concern?

A practical tip: Because CML is a long-term, often decades-long treatment relationship, the milestone conversation — specifically knowing exactly which BCR-ABL percentage you need to hit at 3 months, 6 months, and 12 months — is worth asking for in writing at your first appointment. Many patients on imatinib find that having their own printed monitoring schedule helps them stay engaged with their treatment response over the long term, rather than waiting passively for results to be interpreted at appointments.

compare with other therapies

Compare imatinib vs dasatinib vs nilotinib for newly diagnosed chronic phase CML

This is one of the most nuanced treatment decisions in hematologic oncology — three approved first-line options with meaningfully different efficacy, side-effect profiles, and long-term implications, including the increasingly important question of which drug best positions a patient for eventual treatment-free remission.

What they are and how they differ mechanistically

	Imatinib (Gleevec)	Dasatinib (Sprycel)	Nilotinib (Tasigna)
Generation	1st	2nd	2nd
BCR-ABL binding	Type II — binds inactive conformation	Type I — binds active and inactive	Type II — binds inactive conformation
Potency vs imatinib	Reference	~325x more potent in vitro	~30x more potent in vitro
Additional kinase targets	KIT, PDGFR, ABL	KIT, PDGFR, SRC family kinases	KIT, PDGFR
SRC kinase inhibition	No	Yes — additional mechanism	No
T315I mutation coverage	No	No (dasatinib covers some other resistant mutations)	No
Approved first-line	2001	2010	2010
Generic available	Yes — widely and affordably	Limited	Limited

The type I vs type II binding distinction matters clinically — dasatinib’s ability to bind both active and inactive conformations of BCR-ABL, plus its SRC kinase inhibition, gives it a slightly broader mechanism and better CNS penetration than the other two.

The pivotal head-to-head trials

All three drugs were compared against imatinib in large randomized trials in newly diagnosed chronic-phase CML:

Trial	Comparison	Key PFS/Response finding
IRIS	Imatinib vs interferon (historical)	Established imatinib as standard
DASISION	Dasatinib vs imatinib	Faster and deeper molecular responses with dasatinib; similar OS at 5 years
ENESTnd	Nilotinib vs imatinib	Faster and deeper molecular responses with nilotinib; fewer progressions to accelerated/blast phase

The consistent finding across DASISION and ENESTnd: both second-generation drugs achieve faster and deeper molecular responses than imatinib — meaning BCR-ABL levels fall more quickly and to lower levels. However, long-term overall survival has not been shown to be definitively superior for either second-generation drug over imatinib in the chronic phase setting, partly because patients who develop resistance on imatinib can often be switched successfully to a second-generation TKI.

Molecular response depth and treatment-free remission implications

This is where the comparison has evolved most significantly in recent years. Treatment-free remission — the possibility of stopping therapy entirely while maintaining undetectable BCR-ABL — has become an explicit treatment goal for many patients, particularly younger ones.

Achieving the deep molecular responses required for treatment-free remission attempts (MR4 or MR4.5 — BCR-ABL undetectable or below 0.01% on the International Scale) happens faster and more frequently with second-generation TKIs than with imatinib. Long-term data suggest:

Approximately 40-50% of patients on nilotinib or dasatinib who achieve sustained deep molecular response may be candidates for treatment-free remission attempts
Imatinib patients can also achieve treatment-free remission, but generally takes longer to reach the required depth of response

For a younger patient with a treatment-free remission goal — whether for family planning, quality of life, or simply the desire to stop lifelong therapy — this difference meaningfully favors starting with a second-generation TKI.

Side effect comparison — the most practically important differences

Side effect	Imatinib	Dasatinib	Nilotinib
Fluid retention / edema	Common — periorbital, peripheral	Less common in general; pleural effusion is distinctive	Less common than imatinib
Pleural effusion	Rare	More common — 10-28% (fluid around lungs) — distinctive to dasatinib	Rare
Nausea / GI effects	More prominent	Less prominent	Moderate
Muscle cramps	Common — distinctive to imatinib	Less common	Less common
Cardiovascular events	Less prominent	Pulmonary arterial hypertension (rare but serious)	Arterial occlusive events — peripheral artery disease, heart attack, stroke
QTc prolongation	Less prominent	Less prominent	More prominent — monitoring required
Hyperglycemia	Less common	Less common	More common — diabetes risk
Hepatotoxicity	Present	Present	Present — more prominent
CNS penetration	Limited	Better — relevant for blast crisis with CNS involvement	Limited
Food restrictions	None — taken with food	None	Must be taken on empty stomach — 2 hours after and 1 hour before food

The cardiovascular difference — clinically the most important safety distinction

Nilotinib’s association with arterial occlusive events — peripheral artery disease, myocardial infarction, and stroke — is the most important long-term safety signal in this comparison. These events appear to increase with duration of nilotinib exposure and are more frequent than with imatinib or dasatinib. For patients with pre-existing cardiovascular risk factors (diabetes, hypertension, hyperlipidemia, smoking history, prior cardiac events), this risk profile meaningfully changes the calculus toward imatinib or dasatinib.

Dasatinib’s pleural effusion risk is the equivalent concern for that drug — fluid accumulation around the lungs that can range from asymptomatic (found on routine imaging) to causing significant breathlessness requiring treatment interruption, diuretics, or corticosteroids. For patients with pre-existing lung disease, this is a relevant consideration.

Dosing and practical differences

	Imatinib	Dasatinib	Nilotinib
Dose	400mg once daily	100mg once daily	300mg twice daily
With food	Required — reduces nausea	With or without food	Empty stomach required — strict rule
Pill burden	1 tablet	1 tablet	2 tablets twice daily (4 total/day)
QTc monitoring	Not required	Not required	Required — baseline and periodic ECG

Nilotinib’s twice-daily empty-stomach requirement — similar in principle to abiraterone’s food restriction — is a real adherence consideration. Taking it with food can significantly alter drug exposure, and remembering to take it twice daily on an empty stomach is a more demanding routine than imatinib’s or dasatinib’s once-daily approach.

Risk stratification — how Sokal/ELTS score influences the choice

A patient’s Sokal or ELTS risk score (calculated from age, spleen size, platelet count, and blast percentage at diagnosis) helps guide the first-line choice:

Low risk — imatinib remains a very reasonable first choice; survival outcomes are excellent and treatment-free remission is achievable, though more slowly
Intermediate or high risk — second-generation TKIs are often preferred given faster and deeper responses, lower risk of progression to accelerated or blast phase, and better treatment-free remission prospects

How the practical choice typically unfolds

Imatinib tends to be preferred when:

Cost or access is a significant constraint (generic widely available)
Patient has significant cardiovascular history (avoids nilotinib’s arterial risk)
Patient has pre-existing lung disease or pleural history (avoids dasatinib’s pleural effusion risk)
Low-risk Sokal/ELTS score where excellent outcomes are expected
Older, frailer patient where tolerability is the primary concern

Dasatinib tends to be preferred when:

Treatment-free remission is an explicit goal and faster depth of response is desired
CNS involvement is present or at risk (better CNS penetration)
Patient has cardiovascular risk factors that make nilotinib less appropriate
Twice-daily dosing (nilotinib) or food restriction concerns are relevant
Intermediate or high Sokal/ELTS risk

Nilotinib tends to be preferred when:

Treatment-free remission is the explicit goal and ENESTnd data is the preferred evidence base
Patient has no cardiovascular risk factors, diabetes, or vascular disease history
Intermediate or high Sokal/ELTS risk
Patient can reliably manage twice-daily empty-stomach dosing

Bottom line

This comparison doesn’t have a single right answer — it’s one of the most genuinely individualized treatment decisions in hematology. The three drugs are all legitimate first-line options with decades of supporting data. The key variables that tend to resolve the choice are: cardiovascular risk (favors imatinib or dasatinib over nilotinib), treatment-free remission as an explicit priority (favors second-generation), cost and access (favors imatinib), pre-existing lung disease (favors imatinib or nilotinib over dasatinib), and adherence to complex dosing rules (favors imatinib or dasatinib over nilotinib’s twice-daily empty-stomach requirement). Mapping these against your specific risk score and long-term goals with your hematologist is the essential conversation.

How does testing work

What is treatment-free remission in CML and who is eligible to stop imatinib?

Treatment-free remission (TFR) is one of the most remarkable developments in modern oncology — the possibility that patients with a disease that once required lifelong therapy might be able to stop treatment entirely and remain in remission. It’s also one of the most carefully managed decisions in hematology, because the eligibility criteria and monitoring requirements are specific and non-negotiable.

What treatment-free remission actually means

TFR doesn’t mean the cancer is cured — residual CML cells almost certainly remain in most patients who stop therapy, at levels below the detection threshold of current tests. What it means is that the immune system, in concert with the deep suppression achieved by TKI therapy, is able to keep those remaining cells in check without ongoing drug treatment.

The distinction matters because TFR attempts are managed as a controlled withdrawal under close molecular monitoring — not as a declaration that treatment is finished. If BCR-ABL levels rise above a defined threshold after stopping, TKI therapy is restarted promptly, and the vast majority of patients who lose remission regain it on restarting — making TFR attempts generally safe when managed properly.

The evidence base — key TFR trials

The concept emerged from the STIM trial (2010), which first demonstrated that carefully selected CML patients could stop imatinib and maintain undetectable BCR-ABL. Subsequent trials refined the eligibility criteria and confirmed the findings:

STIM and STIM2 — imatinib TFR; roughly 40% of eligible patients maintained TFR at 2 years
EURO-SKI — largest TFR trial, ~800 patients across multiple TKIs; identified duration of deep molecular response as the strongest predictor of successful TFR
ENESTfreedom and DASFREE — TFR with nilotinib and dasatinib respectively; TFR success rates slightly higher (~50%) than imatinib trials, reflecting deeper responses achieved with second-generation drugs
Re-STIM — showed that patients who failed a first TFR attempt and restarted therapy could make a second TFR attempt successfully

Eligibility criteria — what needs to be true before attempting TFR

The criteria used across major trials and now reflected in NCCN and ELN guidelines are:

Duration of TKI therapy: Most guidelines require at least 5 years of total TKI therapy before a TFR attempt. This ensures sufficient treatment duration to achieve durable disease control.

Depth of molecular response: The patient must have achieved and sustained MR4 (BCR-ABL ≤0.01% on the International Scale) or preferably MR4.5 (BCR-ABL ≤0.0032% or undetectable with sufficient sensitivity). A single measurement is not sufficient — sustained response over time is required.

Duration of deep molecular response: Most guidelines require at least 2 years of sustained MR4 or deeper response before stopping. EURO-SKI data showed that the longer the duration of deep molecular response before stopping, the higher the likelihood of maintaining TFR.

Chronic phase only: TFR is not currently recommended for patients who have been in accelerated or blast phase.

Molecular monitoring capability: The patient must have access to a laboratory that can perform sensitive quantitative PCR testing (capable of detecting BCR-ABL at MR4.5 levels) and must commit to frequent monitoring after stopping.

No prior TKI resistance: Patients who switched TKIs due to resistance (rather than intolerance) generally have lower TFR success rates.

What the monitoring schedule looks like after stopping

This is where TFR diverges most sharply from simply “finishing” a medication. The monitoring intensity after stopping is higher than during stable treatment:

Months 1–6: BCR-ABL PCR every month
Months 7–12: Every 6 weeks
Year 2: Every 3 months
Beyond year 2: Every 3–6 months indefinitely

This frequency reflects the fact that most molecular relapses — approximately 50–60% of all relapses — occur within the first 6 months after stopping. The early intensive monitoring catches these quickly, allowing prompt TKI restart before any clinical progression occurs.

What constitutes molecular relapse — when TKI restarts

Different guidelines use slightly different thresholds, but the most commonly used criterion is:

Loss of major molecular response (MMR) — BCR-ABL rising above 0.1% on the International Scale on a single confirmed measurement, or
Any confirmed loss of MR4 on two consecutive measurements

At the point of molecular relapse, TKI therapy is restarted — typically at the same dose as before stopping. The critical reassurance from trial data is that the vast majority (>95%) of patients who lose TFR regain deep molecular response on restarting — meaning a failed TFR attempt does not permanently compromise the patient’s disease control.

Who is most likely to succeed at TFR

EURO-SKI and other analyses have identified several factors associated with higher TFR success:

Longer duration of deep molecular response before stopping — the single strongest predictor
Longer total TKI treatment duration
Low Sokal risk score at diagnosis
Second-generation TKI — nilotinib and dasatinib TFR rates are modestly higher than imatinib, partly reflecting the deeper responses achieved
Complete molecular response (undetectable BCR-ABL) at time of stopping rather than detectable-but-below-threshold MR4

There is also emerging evidence that immune system factors — specifically natural killer (NK) cell function — play a role in maintaining TFR, which helps explain why some patients with seemingly equivalent disease control maintain TFR while others relapse.

The TFR attempt as a conversation, not just a decision

One important practical point: TFR attempts require explicit patient commitment to the monitoring schedule. A patient who stops imatinib and then misses monthly PCR tests is not in a managed TFR — they’re simply off treatment without safety monitoring. This is why TFR is always described as an “attempt” with a structured protocol rather than simply stopping the medication.

The conversation with your hematologist should specifically cover: which laboratory will do the PCR testing, what level of sensitivity that lab can reliably detect, what the specific restart threshold is, and what the plan is if you miss a monitoring appointment.

Practical implications — why this matters for treatment choice at diagnosis

This context connects back to the imatinib vs dasatinib vs nilotinib comparison: for a newly diagnosed patient with TFR as an explicit long-term goal — particularly younger patients who want the option of stopping therapy before or after having children — choosing a second-generation TKI from the outset may reach the depth of response needed for TFR eligibility faster. For a patient where TFR isn’t a priority (older patient with good imatinib tolerance, cost constraints, or comorbidities that make second-generation TKIs less appropriate), imatinib remains an entirely legitimate path to TFR — just potentially a longer one.

Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Osimertinib is a prescription medication that must only be used under the supervision of a qualified oncologist. Clinical outcomes data is drawn from published Phase III trials; individual results vary. Always consult your healthcare provider and refer to the full prescribing information before making any treatment decisions. Emergency: call your local emergency services or poison control immediately if you experience serious adverse effects.